Home
 /
Papers
 /
Cancer Biology
 /
Critical role of cell competition in gliomagenesis
Preprint
Open access
Top 1% · Validated by QED

Critical role of cell competition in gliomagenesis

Ying Jiang, Ryuhjin Ahn, Arthur Huang +23 more
January 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.01.15.699808
99
%
QED Score
QED Impressions

By establishing that glioma arises through competitive displacement of normal OPCs rather than unchecked proliferation, this work overturns the foundational view of gliomagenesis and identifies mTORC1-dependent competition as a targetable vulnerability for intercepting tumor initiation.

Run full QED analysis
Read paper
Save

Author perspective

What is the most important insight, discovery, or finding from your paper that you would like other scientists to know?
“

Premise is the key for successes. Our study challenges the premise of "war on cancer", and reveals that "peace" may be the best way to manage glioblastoma, one of the deadliest cancer type. Based on our discovery of cell competition as a driving force for glioblastoma, cytotoxic treatments that intend to kill likely result in selective pressure for increased malignancy, while peace-making therapeutic strategies could completely change the game.

”
Hui Zong

QED claims analysis

Summary

Cell competition between pre-malignant Trp53,Nf1-null oligodendrocyte precursor cells (OPCs) and normal OPCs is a necessary driver of gliomagenesis that operates through Nf1-loss-mediated Ras-mTORC1 signaling to generate unique protein species via regulated RNA splicing and translation, and blocking this competition-specific signaling—either by strengthening normal OPCs or by inhibiting mTORC1 in mutant OPCs—prevents both pre-malignant expansion and malignant transformation in mouse models and is relevant to human glioblastomas where normal OPCs are specifically eliminated from tumor regions.

See full analysis
Main Claim 1 –

Trp53,Nf1-Null OPCs Outcompete Normal OPCs Pre-Malignancy

Supporting evidence

  • OPC Competition Persists in Adult Brain Homeostasis
  • OPC Competition Is Local; Clone Expansion Rate Is Size-Independent
Main Claim 2 –

Nf1 Loss Alone Drives OPC Competition in MADM Model

Supporting evidence

  • Nf1 Ras-GAP Loss Activates Ras to Drive OPC Competition
Main Claim 3 –

OPC Competition Is Required for Glioma Initiation and Transformation

Supporting evidence

  • Malignant Glioma Cells Continue Outcompeting Host OPCs In Vivo
  • Competition Blocking Limits Glioma Infiltration Without Reducing Proliferation
Main Claim 4 –

Competition Signaling Enriches Splicing, Translation, and mTORC1 Activation

Supporting evidence

  • MEK Inhibition Cannot Specifically Block OPC Competition Due Toxicity

Abstract

Malignant glioma is incurable. Using a mouse genetic mosaic system to generate sporadic Trp53,Nf1-null OPCs, we previously identified oligodendrocyte precursor cell (OPC) as a cell-of-origin of glioma. Here, we report that pre-malignant Trp53,Nf1-null OPCs outcompete wildtype counterparts during their expansion. Blocking competition by mutating/strengthening wildtype OPCs impeded both pre-malignant progression and malignant expansion of glioma.

“In-tissue” phosphoproteomic profiling revealed an enrichment of phosphopeptides related to RNA splicing and protein translation at the peak of cell competition, suggesting that competitiveness may stem from unique protein species. Among candidates was mTORC1, whose pharmacological inhibition or genetic disruption resulted in a loss of competitiveness in our mouse model. Finally, analysis of patient biopsies and interrogating the role of individual gliomagenic mutations in OPC competition supported its relevance in human gliomas. Together, these findings identified the driving role of competitive interactions among OPCs in gliomagenesis, and suggest unconventional therapeutic strategies to target this process.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?